In a statement made by the British Ministry of Health, it was stated that a group of researchers from Oxford, Sheffield, Liverpool, Newcastle and Birmingham Universities examined the immune response that occurred after the vaccine in healthcare workers who had the first dose of the Pfizer-BioNTech Covid-19 vaccine.
In the statement, it was noted that T cell and antibody responses were analyzed in blood samples taken from 257 healthcare workers who had the first dose of vaccine between December 9, 2020 and February 9, 2021.
In the statement, which reported that 99 percent of those who had the first dose of vaccine had a strong immune response, it was stated that the vaccine also provided protection against the severe disease caused by Covid 19.
In the statement, it was reported that the research results support the view that the second dose of Pfizer-BionTech’s Covid-19 vaccine, which provides high protection with the first dose, can be made after a long time, and that more people in the risk group can be protected by prioritizing the first dose.
In the statement, which stated that the T cell and antibody response in people who received a dose of vaccine after Kovid-19 was higher than those who received a dose of vaccine without Covid-19, it was stated that the T cell and antibody response that occurred after the vaccine was not yet known. .
Britain’s Health Minister Matt Hancock, whose comments were quoted in the statement, said the study revealed more evidence that vaccines provide “excellent” protection against the virus.
Hancock noted that thanks to their “successful” vaccination program, more than 50 percent of adults in the country are vaccinated and they aim to offer vaccines to all adults by July.